About

Multiple myeloma is a cancer of plasma cells, the white blood cells that normally make antibodies, and it often causes no symptoms at first before progressing to bone pain, anemia, kidney problems, and infections. Mezigdomide is an oral drug that binds to a protein called cereblon, part of the cell's built-in disposal system, and redirects it to break down specific proteins that myeloma cells rely on to grow. Because those proteins help drive the cancer, tagging them for destruction may slow or stop the disease in people whose myeloma has returned or stopped responding to earlier treatment.